Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Phase 2 study reporting long-term relapse-free survival with blinatumomab in MRD-positive B-lineage ALL.

Publication · 2024-11-06

More detail is on the way.

Full content is being migrated into the new site. Reach out and a senior contact will send you a copy directly.

All white papers, case studies, publications and blogs.

Peer-reviewed and journal articles.

Talk to a senior contact about the work behind this.